JNJ

Johnson & Johnson

251.71 USD

Last updated Oct 14, 16:10 UTC

Yesterday HIGH

$256.18

Yesterday LOW

$245.19

52w HIGH

$281.07

52w LOW

$184.66

EPS

2.59

PE

97.19

Next Earnings

Jan 20, 2027

Dividends yield

2.03%

Overview News Unusual Options Flow Government Trades Fundamentals

Johnson & Johnson stock is down -5.49% since 30 days ago. The dividend yield is 2.03% and its next earnings date is Jan 20, 2027. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64% of the previous 49 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 75% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

14 Oct 14:54	18 Dec, 2026	230.00	PUT	968	1325
14 Oct 15:10	19 Mar, 2027	270.00	PUT	10	789
14 Oct 15:28	21 Jan, 2028	250.00	CALL	10	819
14 Oct 15:33	17 Sep, 2027	230.00	CALL	11	11
14 Oct 15:38	21 Jan, 2028	175.00	CALL	8	426
14 Oct 15:38	19 Jan, 2029	185.00	CALL	8	4
14 Oct 15:42	23 Oct, 2026	257.50	CALL	206	8953
14 Oct 15:43	23 Oct, 2026	257.50	CALL	6371	8953
14 Oct 15:43	17 Dec, 2027	175.00	CALL	25	392
14 Oct 15:43	15 Dec, 2028	180.00	CALL	25	243

Advanced Data Unlock

Kaustubh Bagalkote

Mon Oct 12, 2026

JPMorgan Chase Could Swing $28 Billion After Earnings

UnitedHealth, JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup report earnings Tuesday. See implied moves and market value at stake.
Chris Katje

Mon Oct 12, 2026

Dow Jones Industrial Average Gets Spotlight: 5 Earnings Reports Representing 25% of ETF’s Assets On Deck

Five of the 30 Dow Jones Industrial Average components report earnings this week. Here are the names.
Benzinga Newsdesk

Fri Oct 9, 2026

Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times

https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html
Benzinga Newsdesk

Fri Oct 9, 2026

Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals

ICOTYDE clinical data highlights2High levels of skin clearance were observed at Week 112, with ≥72% of ICOTYDE-treated patients achieving a Psoriasis Area and Severity Index score (PASI)c of 90 and ≥70% achieving clear
Benzinga Insights

Thu Oct 8, 2026

8 Of 11 Sectors Fall In Thursday Trading As Energy Leads

Three sectors are higher and eight are lower in Thursday's regular session, with the top three split across cyclical, defensive and growth groups. The leaders are separated rather than clustered, with Energy clearly ahead of the next sectors in the ranking.
Benzinga Insights

Wed Oct 7, 2026

9 Of 11 Sectors Fall Wednesday As Defensives Lead

Two of 11 sectors are higher in Wednesday's regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with Health Care and Consumer Staples above the rest of the table.
Benzinga Newsdesk

Wed Oct 7, 2026

Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target

Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $287 price target.
Benzinga Insights

Tue Oct 6, 2026

9 Of 11 Sectors Rise In Tuesday Trading As Defensives Lead

Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Utilities well ahead of the next group.
Benzinga Newsdesk

Tue Oct 6, 2026

RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290

RBC Capital analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $287 to $290.
Benzinga Insights

Mon Oct 5, 2026

8 Of 11 Sectors Rise In Monday Trading As Leaders Split

Eight sectors are higher and three are lower in Monday's regular session, with growth, cyclical and defensive sectors split across the top three positions. The leaders are separated rather than clustered.

Guggenheim

Wed Oct 7, 15:02

buy

confirm
RBC Capital

Tue Oct 6, 15:14

buy

confirm
Citigroup

Mon Oct 5, 21:43

buy

confirm
JP Morgan

Tue Sep 29, 15:29

hold

confirm